Introduction {#sec1}
============

Hepatitis E is the infection of the liver caused by a virus known as the hepatitis E virus (HEV) and has posed severe public health hazards around the world. HEV has four major genotypes (1--4) that are globally distributed into different epidemiological patterns based on socioeconomic factors and ecology ([@bib19]). HEV genotypes 1 and 2 infect humans solely ([@bib3]). Generally, genotype 1 accounts for the epidemics in some parts of Asia, while genotype 2 is more prevalent in Africa, Mexico, and other developing countries ([@bib7]). Genotypes 3 and 4 are zoonotic with an expanded host range ([@bib21]), while there have been noted chronic HEV infections in immunosuppressed patients (Honer zu [@bib13]). Genotype 3 is prevalent worldwide, while genotype 4 is mainly present in Asia. Besides, genotypes 5 and 6, which primarily infect wild boar, have been found in Japan ([@bib23]; [@bib24]). Recently, new genotypes, known as HEV-7 and HEV-8, were also found to infect camels and humans ([@bib5]).

Currently, HEV's diagnosis depends on specific serological and nucleic acid tests, as the clinical manifestations and routine laboratory measures of HEV are similar to those of other acute hepatitis ([@bib27]). There are four major methods for diagnosing hepatitis E, including the detection of anti-HEV IgM and IgG antibodies, the antigen (Ag), and HEV RNA. Presently, the clinical diagnosis of acute hepatitis E cases mainly depends on the serological detection of anti-HEV antibodies ([@bib8]). However, equivalence, sensitivity, and specificity in the results of the HEV Enzyme-linked Immunosorbent Assay (ELISA) kits tend to differ between manufacturers, leading to discrepancies in the rates of anti-HEV antibodies among different populations ([@bib12]; [@bib9]), together with the HEV genome heterogeneity, and the different antigenic structure of HEV proteins. Moreover, cross-reactions of anti-HEV IgM with the Epstein-Barr virus (EBV) and cytomegalovirus (CMV) antibodies have been reported, which cause false-positive results ([@bib14]). Currently, the development of the HEV RNA assay kits is in the early stages in China and has not yet been widespread. Thus, the clinical diagnosis of HEV infection still mainly relies on serological assays with a few reports of hepatitis E misdiagnoses occurring in China.

In the present study, the performance of four commercial serological assays and PCR assay for the detection of HEV infection was evaluated, and the possibility of misdiagnosing of this infection using serological detection alone was determined.

Experimental {#sec2}
============

Materials and Methods {#sec3}
---------------------

**Samples**. From March 2014 to March 2018, 364 serum samples were collected from Tianjin Third Central Hospital and Tianjin Medical University General Hospital. A total of 86 cases were diagnosed with acute viral hepatitis E ([@bib16]; [@bib10]), 91 cases with rheumatic diseases (RD) including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), and 91 cases with viral hepatitis by CMV or EBV according to the diagnostic guidelines of each disease. Meanwhile, 96 healthy volunteers were included in this study. Five milliliters of venous blood was collected and agglutinated for 10 min at 37°C, and subsequently centrifuged at 3,000 × g for 15 min at 4°C. The serum was taken and stored at --80°C before analysis. This study received approval from the Branch of Tianjin Third Central Hospital Ethics Committee (2019028). Our study was non-interventional and did not involve any specific sampling or addition to the usual procedures. An anonymized database provided analytical support. Therefore, the ethics committee waived the need for patient consent.

**HEV serological assays**. The commercially available HEV ELISA kits were selected with Wantai (Beijing, China), Kehua (Shanghai, China), Lizhu (Zhuhai, China), and Genelabs (Singapore, Singapore) for the detection of both IgM and IgG antibodies. For the HEV Ag assay, the Wantai was the only available commercial provider for the ELISA kit in China. All the experimental operations were performed according to the instructions recommended by manufacturers. Results of the ELISA tests were listed as ratios (s/co), and interpretations were made as advised in the instructions.

**The HEV RNA assay**. One-step reverse transcription-quantitative polymerase chain reaction (RT-qPCR) assay was set up by our research team and had been approved for clinical use. Primers and probes were designed based on a multiple sequence alignment of the HEV genome sequences in the ORF3 region, and synthesized by the Sangon Biotech Company (Shanghai, China): forward primer, 5'-GGTGGTTTCTGGGGT-GAC-3' (T~m~ = 61.2°C); reverse primer, 5'-AGGGGTTG-GTTGGATGAA-3' (T~m~ = 61.2°C); probe, 5'-TGATTC-TCAGCCCTTCGC-3' (T~m~ = 62.5°C). NCBI-Primer-BLAST searches for the primers and probe showed that the genetic sequences of the different HEV genotypes 1--4 were highly conserved in the ORF3 region. Firstly, the target fragment of 70 bp was amplified from the strain of HEV genotype 4 (CHNXJ-SW13) by the forward and reverse primers mentioned above, and then inserted the fragment into Promega T-easy Vector (3105 bp) to obtain the standard plasmid. Serial dilutions plasmids of 5 × 10^0^ \~ 5 × 10^9^ copies/2 μl were obtained by 10-fold dilution, and the standard curve was established. Total RNA was extracted from 140 μl serum using TIANamp Virus RNA Kit (Tiangen, Beijing, China). The One-Step PrimeScript' RT-PCR Kit (Takara, Dalian, China) enabled the performance of RT-qPCR in a total 20-μl reaction system, including 10 μl GoTaq Probe qPCR Master Mix (1×), 0.4 μl GoScript RT Mix for one-step RT-qPCR (1×), 1 μl forward primer (500 mM), 1 μl reverse primer (500 mM), 0.5 μl probe (250 nM), 5.1 μl RNase-Free H~2~O and 2 μl RNA template or standard plasmid of HEV. Subsequently, the reaction was conducted with the MX3000P Real-Time QPCR System (Aligent, California, USA). The conditions for PCR amplification involved the following: 1 cycle at 45°C for 30 min, 1 cycle at 95°C for 15 min, followed by 45 cycles at 95°C for 10 sec, at 55°C for 20 sec and at 72°C for 15 sec. The expression of the HEV RNA was calculated according to the standard curve established by plasmids with different dilutions.

**Data analysis**. Commercially available software was used for all the statistical analyses (MedCalc, version 18.2, Belgium). The receiver operating characteristic (ROC) curve was used to analyze the diagnostic performances for anti-HEV IgG and IgM assays. Agreements between different kits were assessed by the Kappa statistic. The level of agreement was defined by the Kappa coefficient as excellent (\> 0.8), substantial (0.6--0.8), moderate (0.4--0.6), fair (0.2--0.4), and poor (\< 0.2) ([@bib20]). A *p*-value of less than 0.05 was considered statistically significant. Additionally, two-sided 95% confidence intervals (CI) were calculated.

Results {#sec4}
=======

**Performance of anti-HEV IgM assays**. The diagnostic performance characteristic of each anti-HEV IgM kit was determined by the ROC curve. As shown in Table [I](#tbl1){ref-type="table"}, the area under the curve (AUC) value of the ELISA kits ranged from 0.909 to 0.93. The sensitivity among the 86 acute HEV infections ranged from 82.6% to 86% (Table [I](#tbl1){ref-type="table"}), suggesting an excellent agreement (Kappa: 0.819--1) in anti-HEV IgM antibody detection between the ELISA kits (Table [II](#tbl2){ref-type="table"}). All the anti-HEV IgM assays evaluated demonstrated good specificities (97.8--100%), except for two false-positive results obtained from the RD cases detected by the Genelabs ELISA kit. No positive results were shown in CMV/EBV infected patients by all the assays (Table [I](#tbl1){ref-type="table"}), which demonstrated that there were no cross-reactions of IgM against CMV and EBV.

###### 

Diagnostic performance of anti-HEV IgM assays.

![](pjm-69-2-217-t001)

  Commercial tests   \% Sensitivity (95% CI)   \% Specificity (95% CI)   \% PPV (95% CI)     \% NPV (95% CI)     AUC (95% CI)           *p*       \% Specificity with RD (95% CI)   \% Specificity with CMV/EBV (95% CI)   \% Specificity with healthy (95% CI)
  ------------------ ------------------------- ------------------------- ------------------- ------------------- ---------------------- --------- --------------------------------- -------------------------------------- --------------------------------------
  Wantai             84.9 (75.5--91.7)         100 (98.7--100)           100 (100--100)      95.5 (92.8--97.2)   0.924 (0.892--0.949)   \< 0.01   100 (100--100)                    100 (100--100)                         100 (100--100)
  Kehua              86.0 (76.9--92.6)         100 (98.7--100)           100 (100--100)      95.9 (93.2--97.5)   0.930 (0.899--0.954)   \< 0.01   100 (100--100)                    100 (100--100)                         100 (100--100)
  Lizhu              83.7 (74.2--90.8)         100 (98.7--100)           100 (100--100)      95.2 (92.5--97.0)   0.919 (0.886--0.945)   \< 0.01   100 (100--100)                    100 (100--100)                         100 (100--100)
  Genelabs           82.6 (72.9--89.9)         99.3 (97.4--99.9)         97.3 (89.9--99.3)   94.8 (92.1--96.7)   0.909 (0.875--0.937)   \< 0.01   97.8 (94.8--100)                  100 (100--100)                         100 (100--100)
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Concordance for anti-HEV IgM assays in the diagnosis of the acute HEV infections.
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  Commercial tests   \% Concordance   Kappa (95% CI)
  ------------------ ---------------- ----------------------
  Wantai                              
  Kehua              98.8             0.950 (0.852--1.000)
  Lizhu              98.8             0.953 (0.862--1.000)
  Genelabs           95.3             0.819 (0.648--0.990)
  Kehua                               
  Lizhu              97.7             0.903 (0.771--1.000)
  Genelabs           96.5             0.860 (0.706--1.000)
  Lizhu                               
  Genelabs           96.5             0.868 (0.722--1.000)

**Performance of anti-HEV IgG assays**. The AUC value (0.827--0.929) of the four distinct anti-HEV IgG kits are shown in Table [III](#tbl3){ref-type="table"}. The sensitivity among the acute HEV infection patients ranged from 87.2% to 91.9% and showed a substantial agreement with Kappa coefficients from 0.752 to 0.927 between each different ELISA kit (Table [III](#tbl3){ref-type="table"} and IV). However, the specificities of anti-HEV IgG among the non-HEV population showed significant inconsistency between each ELISA kit (Table [IV](#tbl4){ref-type="table"}). The specificity of the Kehua (96.9--98.9%) and Genelab (96.7--98.9%) tests were significantly higher when compared with the Wantai (64.6--81.3%) and Lizhu assays (69.8--83.5%) (Table [III](#tbl3){ref-type="table"}).
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Diagnostic performance of anti-HEV IgG assays.
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  Commercial tests   \% Sensitivity (95% CI)   \% Specificity (95% CI)   \% PPV (95% CI)     \% NPV (95% CI)     AUC (95% CI)           *p*       \% Specificity with RD (95% CI)   \% Specificity with CMV/EBV (95% CI)   \% Specificity with healthy (95% CI)
  ------------------ ------------------------- ------------------------- ------------------- ------------------- ---------------------- --------- --------------------------------- -------------------------------------- --------------------------------------
  Wantai             91.9 (83.9--96.7)         74.8 (69.3--79.8)         53.0 (47.7--58.3)   96.7 (93.6--98.4)   0.833 (0.791--0.870)   \< 0.01   79.2 (71.0--87.3)                 81.3 (73.3--89.3)                      64.6 (55.0--74.1)
  Kehua              87.2 (78.3--93.4)         97.5 (94.9--99.0)         91.5 (83.7--95.7)   96.1 (93.4--97.7)   0.923 (0.891--0.949)   \< 0.01   98.9 (96.6--100)                  97.8 (94.8--100)                       96.9 (93.4--100)
  Lizhu              89.5 (81.1--95.1)         75.9 (70.4--80.8)         53.5 (48.0--58.9)   95.9 (92.6--97.8)   0.827 (0.784--0.865)   \< 0.01   83.5 (75.9--91.1)                 74.7 (65.8--83.6)                      69.8 (60.6--79.0)
  Genelabs           88.4 (79.7--94.3)         97.5 (94.9--99.0)         91.6 (83.9--95.8)   96.4 (93.8--98.0)   0.929 (0.898--0.953)   \< 0.01   98.9 (96.6--100)                  96.7 (93.0--100)                       97.9 (95.0--100)
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Concordance for anti-HEV IgG assays.
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  Commercial tests   Concordance of HEV   Concordance of RD      Concordance of CMV/EBV   Concordance of healthy                                          
  ------------------ -------------------- ---------------------- ------------------------ ------------------------ ------ ------------------------ ------ ------------------------
  Wantai                                                                                                                                                  
  Kehua              95.3                 0.753 (0.524--0.982)   80.2                     0.081 (--0.069--0.231)   81.3   0.069 (--0.102--0.239)   68.8   0.147 (0.015--0.279)
  Lizhu              98.8                 0.927 (0.785--1.000)   91.2                     0.712 (0.525--0.898)     88.5   0.809 (0.664--0.954)     94.8   0.882 (0.782--0.982)
  Genelabs           96.5                 0.805 (0.592--1.000)   80.2                     0.081 (--0.069--0.231)   82.4   0.153 (--0.064--0.369)   67.7   0.111 (--0.007--0.229)
  Kehua                                                                                                                                                   
  Lizhu              96.5                 0.823 (0.629--1.000)   84.6                     0.107 (--0.087--0.300)   76.9   0.125 (--0.034--0.283)   74.0   0.183 (0.238--0.341)
  Genelabs           96.5                 0.837 (0.658--1.000)   100                      1.000 (1.000--1.000)     98.9   0.795 (0.403--1.000)     99.0   0.852 (0.566--1.000)
  Lizhu                                                                                                                                                   
  Genelabs           95.3                 0.752 (0.520--0.984)   84.6                     0.107 (--0.087--0.300)   78.0   0.183 (0.001--0.366)     72.9   0.139 (--0.005--0.282)

**The HEV Ag and HEV RNA assays**. A total of 36 acute HEV patients were positive for the HEV Ag using the Wantai ELISA kit, with no positive cases found among the non-HEV infection patients. A total of 44 acute HEV infection patients were positive for HEV RNA. The consistency rate between the HEV Ag and RNA was 90.7% (78/86), as shown in Table [V](#tbl5){ref-type="table"}. The two methods had a substantial agreement with a Kappa coefficient of 0.787 (0.656--0.918). Furthermore, six of the 86 samples were positive for HEV RNA but negative for anti-HEV IgM and IgG antibodies, and the HEV Ag by all ELISA kits (Fig. [1](#fig1){ref-type="fig"}).
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Consistency for HEV Ag and HEV RNA assays in the diagnosis of the acute HEV infections.
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                    HEV RNA +, n (%)   HEV RNA −, n (%)   Total, n (%)
  ----------------- ------------------ ------------------ --------------
  HEV Ag +, n (%)   36 (41.86)         0 (0)                36 (41.86)
  HEV Ag −, n (%)   8 (9.3)            42 (48.84)           50 (58.14)
  Total, n (%)      44 (51.16)         42 (48.84)         86 (100)

![Flow diagram for patients with acute viral hepatitis E.](pjm-69-2-217-g001){#fig1}

Discussion {#sec5}
==========

To date, the identification of serological markers in HEV infections using accurate diagnostic assays remain a challenge. There are a plethora of issues regarding the specificity and sensitivity of HEV serological assays in epidemiological and clinical settings that require urgent attention. In this present study, we evaluated four dominant, commercially available anti-HEV IgM and IgG assays, as well as the HEV Ag and HEV RNA to investigate the misdiagnosis's current status rely on the current measurements.

Anti-HEV IgM appears in the early phase of acute hepatitis E. The antibodies can be detected as early as four days after the onset of jaundice and last up to five months ([@bib17]). There are two main methods in anti-HEV IgM serological assays: the capture method with anti-human IgM μ chain (Wantai, Kehua and Lizhu), and the indirect method (Genelabs). The sensitivity and specificity of different methods present variations in anti-HEV IgM assays with a recent study demonstrating a high cross-reactivity of HEV IgM compared to EBV and CMV ([@bib9]). However, in the present study, no false-positive results due to cross-reaction with EBV- or CMV-infected patients were observed, indicating the highly specific nature of the anti-HEV IgM assays. Moreover, these findings were found to be consistent with those of the other groups, including immunocompromised patients ([@bib1]) and infections with HEV genotype 3 (Legrand-[@bib18]). The Genelabs ELISA kit detected two false-positive results obtained from patients with RD. This finding supports the opinion that the capture method using the antihuman IgM μ chain is more specific than the indirect method using the anti-HEV IgM assay.

In general, the detection of anti-HEV IgG is usually used as an indicator of past infection. However, the appearance of the anti-HEV IgG antibody is early, which could be used in the clinical diagnosis of acute HEV infection ([@bib2]). The Qatar research group found that Wantai HEV-IgG assays revealed high sensitivity and specificity with excellent Kappa concordance using different enzyme immunoassays in assessing seroprevalence of HEV antibodies ([@bib4]). However, a significant discrepancy in anti-HEV IgG results between different assay kits in the non-HEV population was found in our study. The positive rates were significantly higher by the Wantai and Lizhu kits than those of Kehua and Genelabs. A Korean research compared anti-HEV IgG antibody results using the Genelabs and Wantai ELISA kits to estimate HEV serum prevalence in the Korean population ([@bib22]). They found a significant inconsistency in the results between the two assays, which was also observed in our study. Therefore, epidemiological investigations of HEV in the population may lead to significant inconsistencies when different kits are used. The Kehua and Genelabs IgG assays had high specificities in the non-HEV population and could be used in the clinical diagnosis of HEV. On the other hand, the Wantai and Lizhu IgG assays were more suitable for epidemiological investigations because the positive rates in the non-HEV population were too high to distinguish the acute HEV infection from the previous disease.

In this study, all four anti-HEV IgG serological assays used the indirect method. There are two major types of antigens coated on the plates for binding of anti-HEV IgG antibodies, including synthetic peptides and recombinant proteins ([@bib15]; [@bib25]). The use of the recombinant ORF2-encoded protein in numerous serological studies has revealed its significant efficacy in the identification of antibodies against various HEV strains ([@bib6]; [@bib17]). Since recombinant proteins can replicate the HEV neutralizing epitope better than the synthetic peptides, the results in the Wantai anti-HEV IgG assay were more sensitive. A French research group also substantiated that the Wantai IgG assay was the most sensitive amongst all other eight commercial ELISA kits used to detect HEV of genotypes 1 and 3 ([@bib1]). The results suggested that the anti-HEV IgM assay was superior in the diagnosis of acute HEV infection due to its good specificity when paired with the Wantai anti-HEV IgG assay, which could improve the accuracy of diagnosis.

The latest reports have indicated that this novel HEV Ag is a resourceful serum marker to detect the acute HEV infection and has a good consistency with HEV RNA ([@bib26]; [@bib28]; [@bib11]; [@bib27]). Our findings in this study also supported this view. However, all the HEV Ag positive samples showed positive anti-HEV IgM results (Fig. [1](#fig1){ref-type="fig"}), which provided no direct evidence to support that Ag detection could improve diagnostic efficiency. Furthermore, six samples were only positive for HEV RNA but negative for anti-HEV IgM and IgG, as well as Ag in all ELISA kits employed, which showed that 6.98% of acute HEV infection patients have a chance to be misdiagnosed if reliant on serological assays detection alone. It indirectly indicates that HEV RNA detection can improve diagnostic efficiency. However, despite the highly specific and sensitive capability of some PCR assays for the detection of HEV RNA, their utility has been restricted due to the short period of HEV viremia detection. Therefore, the incidence of acute HEV infection cannot be completely ruled out by a negative HEV PCR result.

In conclusion, for the successful diagnosis of acute viral hepatitis E, a combination of nucleic acid and serological tests is imperative to provide excellent specificity and sensitivity to the diagnosis. However, we also observed significant inconsistencies between the serological and HEV RNA assays; thereby, caution is warranted while interpreting the results of both serological and molecular tests in HEV diagnosis.
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